Here's Why Abeona Therapeutics Inc. Stock Spiked Today
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after an important announcement concerning a candidate that succeeded in an early-stage trial earlier this month. Although the initiation of a pivotal expansion to the study is indeed good news, that pop had fizzled to a gain of 3.3% as of 12:03 p.m. EDT.
Abeona Therapeutics is developing ABO-102 as a potential gene therapy for the treatment of MPS IIIA, a rare metabolic disease caused by a faulty SGSH gene. There are no available treatments for the life-threatening disorder, but results of a small, early stage clinical trial announced earlier this month suggest Abeona could have the first.
Image source: Getty Images.
Source: Fool.com
Abeona Therapeutics Inc. Aktie
Die Community zeigt eine Präferenz für Buy-Einschätzungen bei Abeona Therapeutics Inc..
Mit einem Community-Kursziel von 13 € für Abeona Therapeutics Inc. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 5.05 € gesehen.
